- PDUFA target action date of May 8, 2027 - If approved, encaleret will be the first and only approv

Allspring Global Investments Holdings LLC cut its holdings in BridgeBio Pharma, Inc. (NASDAQ: BBIO)

When a late-stage clinical trial misses a primary endpoint, the market reaction rarely distributes e

Wall Street analysts change outlook on top names. Complete view of analyst rating changes including

HC Wainwright & Co. analyst Raghuram Selvaraju maintains BridgeBio Pharma (NASDAQ:BBIO) with

BridgeBio Pharma (BBIO) remains a "Strong Buy," driven by regulatory approvals, robust pipeline prog

PALO ALTO, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeB

BridgeBio Pharma hit a 52-week high after a rival's phase III setback boosts confidence in Attruby's

Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome

BridgeBio Pharma (BBIO) witnessed a jump in share price last session on above-average trading volume

U.S. stocks higher, Nasdaq up 150+ points. Aehr Test Systems shares rose 13.6%. Other big gainers in

Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's

Stocks moving: RPGL +54.5%, EDBL +42.5%, SDOT +27.4%, BJDX +24.6%, AP +19.9%, SUNE +18%, ALNY +15.3%

BBIO builds on Attruby's launch as rising rare disease diagnoses and late-stage pipeline candidates

BBIO's outlook hinges on Attruby growth, upcoming drug launch catalysts and execution as it seeks to

BridgeBio Pharma BBIO has become a harder stock to judge after its sharp rare-disease run. Attruby i

- Acoramidis initiation was associated with rapid kidney-protective activity as exhibited in a hemod

- Acoramidis initiation was associated with rapid kidney-protective activity as exhibited in a hemod

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-st

- Preferred equity investment led by Sixth Street and with participation from HealthCare Royalty, a

- Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-bre

- Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-bre

PALO ALTO, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeB

BridgeBio will also share an oral presentation and four posters at the meeting highlighting quality

PALO ALTO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeB

Mid-Day Stocks: Stocks are trading lower on Wednesday, as oil and yields move higher. Once again, it

- Accepted for Priority Review with PDUFA target action date of November 27, 2026, and poised to lau

BridgeBio Pharma (NASDAQ:BBIO | BBIO Price Prediction) received a Neutral initiation from Citi Neutr

BridgeBio Pharma NASDAQ: BBIO executives used a BofA healthcare conference appearance in Las Vegas t

BridgeBio Pharma, Inc. (BBIO) Presents at Bank of America Global Healthcare Conference 2026 Transcri

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of b

BridgeBio Pharma shares Phase 3 trial update, but early data show progress for rare muscle disease t

Ten large-cap stocks sank last week as weak earnings, lowered guidance, analyst downgrades, and deal

BridgeBio stock rises after Phase 3 trial shows its drug helped children with achondroplasia grow fa

  On Friday, 1043 companies hit new 52-week lows.

  Friday's session saw 466 companies set new 52-week highs.

Stocks That Hit 52-Week Lows On Wednesday